Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market-ready Advicenne Seeks Partners and €40m VC Funds

Executive Summary

With a focus on pediatric neurology and nephrology, Dr Luc-André Granier, founder, CEO and medical director of the 10-year old Nimes, France-based Advicenne Pharma SA, tells Scrip how he is looking to raise €40m from VCs in the next two years, while looking for partners to complete development of and commercialize his market-ready and late Phase II assets.

You may also be interested in...



Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round

Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.

Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO

La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.

Primex Nears Market With Oral Pediatric Sedation Solution

Switzerland’s fast-growing critical-care company Primex has submitted for approval what it believes is the first oral solution for the mild to moderate sedation of anxious children undergoing surgical and diagnostic procedures, with a launch in Europe penciled in for a year’s time.

Topics

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel